Sign Up to like & get
recommendations!
0
Published in 2019 at "Cancer cell"
DOI: 10.1016/j.ccell.2019.11.001
Abstract: Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally bioavailable small-molecule inhibitor VTP50469. Cell lines carrying…
read more here.
Keywords:
mll;
mll rearranged;
menin mll;
mll inhibitor ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c00789
Abstract: Targeting the menin-MLL protein-protein interaction is being pursued as a new therapeutic strategy for the treatment of acute leukemia carrying MLL-rearrangements (MLLr leukemia). Herein, we report M-1121, a covalent and orally active inhibitor of the…
read more here.
Keywords:
orally active;
menin;
covalent;
interaction ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2045947
Abstract: ABSTRACT Introduction Chromosomal translocations involving the mixed-lineage leukemia (MLL, KMT2A, MLL1) genes result in the production of MLL fusion proteins, which cause abnormal transcriptional regulation leading to acute leukemia (AL). Menin (MEN1) protein is essential…
read more here.
Keywords:
interaction inhibitors;
menin mll;
leukemia;
mll ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Blood"
DOI: 10.1182/blood.2020005037
Abstract: The interaction of Menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and potential therapeutic opportunity against NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3…
read more here.
Keywords:
inhibition;
flt3;
combined menin;
menin mll ... See more keywords